1. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database.
- Author
-
Castillo, Jorge J., Olszewski, Adam J., Kanan, Sandra, Meid, Kirsten, Hunter, Zachary R., and Treon, Steven P.
- Subjects
- *
WALDENSTROM'S macroglobulinemia , *CANCER-related mortality , *EPIDEMIOLOGY of cancer , *COMPETING risks , *PATIENTS , *DIAGNOSIS - Abstract
Waldenström macroglobulinaemia ( WM) is a rare and incurable lymphoma. Given that the survival of WM patients can be prolonged, our objective was to describe trends in overall survival ( OS) and analyse competing risks of death in patients with WM. The analysis included 5784 patients diagnosed with WM between 1991 and 2010 from the Surveillance, Epidemiology and End Results ( SEER) database. Multivariate hazard models for OS and cumulative incidence of death were fitted according to epoch of diagnosis (1991-2000 vs. 2001-10) while adjusting for age, sex, race, histology, site of involvement and registry. Median OS for the 1991-2000 and the 2001-10 cohorts was 6 and 8 years, respectively ( P < 0·001). In the multivariate analysis, better OS [hazard ratio ( HR) 0·73, 95% confidence interval ( CI) 0·67-0·79; P < 0·001] was seen in the 2001-10 cohort. Survival benefits were identified, for the 2001-10 cohort, in almost every stratum analysed, with the exception of patients aged <50 years and blacks. In the multivariate competing-risk analysis, the 2001-10 cohort experienced lower rates of WM-related ( HR 0·57, 95% CI 0·49-0·66; P < 0·001) and non- WM-related deaths ( HR 0·72, 95% CI 0·66-0·79; P < 0·001). In conclusion, there have been significant improvements in OS, WM-related and non- WM-related mortality in patients with WM diagnosed in the last decade. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF